Fundamental index

600572.SS Zhejiang CONBA Pharmaceutical Co.,Ltd.

Healthcare · Drug Manufacturers - General · CN · as of 2026-08-17

C
Fundamental score
61.71

Reasons

  • Valuation 96: PE n/a, EV/EBITDA n/a, FCF yield 8.1%
  • Balance 75: debt/equity n/a, current ratio 1.98, Altman Z 3.97
  • Quality 46: ROE 6.9%, ROIC n/a, net margin 7.2%

Risk flags

No major cached red flags

Component scores

Quality46
Growth50
Balance75
Valuation96
Cash flow36

Key metrics

ROE
6.9% higher is usually better
-10%35%+
weak < 0%ok >= 10%strong >= 20%
ROICn/a
Net margin
7.2% higher is usually better
-10%35%+
weak < 0%ok >= 10%strong >= 20%
Revenue growthn/a
Debt / equityn/a
Current ratio
1.98 above 1 is generally healthier
03+
risk < 1.0ok >= 1.0strong >= 2.0
Altman Z-score
3.97 higher usually means lower distress risk
04+
distress < 1.8grey 1.8-3.0safer > 3.0
PE ration/a
EV / EBITDAn/a
FCF yield
8.1% higher cash-flow yield is usually better
-5%15%+
weak < 0%ok >= 3%strong >= 8%

Revenue

7.02B 5.91B 7.02B 6.77B 5.91B 6.57B 6.00B 6.73B 6.52B 6.47B 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: revenue values.

Net income

2.02B -345.63M 815.16M -345.63M 453.30M 2.02B 358.12M 591.57M 622.42M 474.36M 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: net income values.

Free cash flow

863.73M 166.15M 166.15M 656.71M 789.30M 321.56M 863.73M 689.50M 721.90M 795.35M 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: free cash flow values.

Growth metrics

32.6% -12.7% 32.6% -3.6% -12.7% 11.2% -8.6% 12.2% -3.2% -0.6% 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: growth metrics values.

Abbreviations and definitions

ROE
ROE measures how much net profit a company generates from shareholders' equity.
ROIC
ROIC compares operating profit after tax with the capital invested in the business.
Net margin
Net margin shows how much net profit remains from revenue.
Revenue growth
Revenue growth measures how sales changed versus the comparable prior period.
Debt / equity
Debt to equity compares company debt with shareholders' equity.
Current ratio
Current ratio compares short-term assets with short-term liabilities.
Altman Z-score
Altman Z-score is a model estimating bankruptcy risk from financial ratios.
PE ratio
PE compares market price with earnings per share.
EV / EBITDA
EV/EBITDA compares total company value with operating earnings before depreciation and amortization.
FCF yield
FCF yield compares free cash flow with market value.
Revenue
Revenue is the total amount generated from selling goods or services before expenses.
Net income
Net income is profit after operating costs, interest, taxes and other expenses.
Free cash flow
Free cash flow is cash left after operating cash flow covers capital expenditures.
Growth metrics
Growth metrics summarize changes in revenue, profit or EPS versus a prior period.
EPS
EPS is net income allocated to each share.
EBITDA
EBITDA is earnings before interest, taxes, depreciation and amortization.
TTM
TTM is a rolling last-12-month view instead of one fiscal year.

This page is an automated factual summary of cached FMP data, not investment advice. Always verify source filings and liquidity before making decisions.